InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | RUBINSTEIN JULIE | President and COO | Sale | 19.0K | $14.23 | $271K | 377.8K | View ↗ | |
| 2026-04-24 | RUBINSTEIN JULIE | President and COO | Sale | 19.1K | $14.02 | $267K | 382.1K | View ↗ | |
| 2026-04-23 | RUBINSTEIN JULIE | President and COO | Sale | 19.1K | $13.74 | $262K | 386.5K | View ↗ | |
| 2026-04-22 | RUBINSTEIN JULIE | President and COO | Sale | 19.1K | $14.13 | $269K | 390.8K | View ↗ | |
| 2026-04-21 | RUBINSTEIN JULIE | President and COO | Sale | 30.9K | $14.66 | $454K | 395.1K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $277.0M+54.8% | $179.0M+5.1% | $170.3M-8.1% | $185.3M+20.1% | $154.3M |
| Cost of revenue | $71.4M-1.0% | $72.1M-4.6% | $75.6M+30.5% | $57.9M+17.5% | $49.3M |
| Research and development | $93.8M-8.9% | $103.0M-15.7% | $122.1M-13.9% | $141.8M-0.4% | $142.3M |
| Sales and marketing | $94.6M+11.6% | $84.8M-4.3% | $88.6M-7.3% | $95.6M+0.1% | $95.5M |
| General and administrative | $72.7M-0.1% | $72.8M-13.3% | $83.9M-5.2% | $88.5M+18.8% | $74.5M |
| Amortization of intangible assets | $1.7M-0.2% | $1.7M+0.2% | $1.7M+0.0% | $1.7M+0.0% | $1.7M |
| Impairment of long-lived assets | $0-100.0% | $7.2M-71.7% | $25.4M | — | — |
| Total operating expenses | $334.1M-2.2% | $341.5M-14.0% | $397.3M+3.1% | $385.5M+6.1% | $363.3M |
| Loss from operations | -$57.1M+64.9% | -$162.5M+28.4% | -$227.0M-13.4% | -$200.2M+4.2% | -$209.0M |
| Interest and other income, net | $9.4M-35.0% | $14.5M-6.4% | $15.5M+282.9% | $4.1M+143.2% | $1.7M |
| Interest expense | -$11.8M-1.7% | -$11.6M+16.1% | -$13.8M-225.6% | -$4.2M | — |
| Net loss | -$59.5M+62.7% | -$159.6M+29.2% | -$225.3M-12.4% | -$200.4M+3.3% | -$207.3M |
| Add: Net (income) loss attributable to noncontrolling interest | -$42K-140.8% | $103K+90.7% | $54K | — | — |
| Net loss attributable to Adaptive Biotechnologies Corporation | -$59.5M+62.7% | -$159.5M+29.2% | -$225.3M-12.5% | -$200.2M+3.4% | -$207.3M |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | -$390+63.9% | -$1K+30.8% | -$2K-11.4% | -$1K+5.4% | -$1K |
| Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | -$390+63.9% | -$1K+30.8% | -$2K-11.4% | -$1K+5.4% | -$1K |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic | $151.72B+3.1% | $147.10B+1.9% | $144.38B+1.3% | $142.52B+1.5% | $140.35B |
| Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted | $151.72B+3.1% | $147.10B+1.9% | $144.38B+1.3% | $142.52B+1.5% | $140.35B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Thermo Fisher ranks sixth by Quant as stock falls on Q1 results
Adaptive Biotechnologies: Strong Sequencing, Weak Margin Of Safety
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
Mid-cap healthcare stocks with A grade EPS revisions ahead of earnings
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On
A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer Agreements
Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look
Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a Year
Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price
Adaptive Biotechnologies targets 30%+ clonoSEQ test volume growth in 2026 while expanding margins and data partnerships